Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 0
---
June 30,  
    December 31, 

    2025  
    2024 

    (unaudited)  

    ASSETS   

    Current assets: 

    Cash   
    $754,323  
    $1,266,131 
  
    Prepaid expenses 
     75,288  
     57,874 
  
    Total current assets  
     829,611  
     1,324,005 

    Total assets   
    $829,611  
    $1,324,005 

    LIABILITIES AND STOCKHOLDERS’ EQUITY  

    Current liabilities: 

    Trade accounts payable and accrued liabilities 
    $254,956  
    $587,536 
  
    Due to related parties  
     93,432  
     93,432 
  
    Total current liabilities 
     348,388  
     680,968 

    Total liabilities 
    $348,388  
    $680,968 

    Stockholders’ Equity 

    Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. 
     -  
     - 
  
    Common Stock, no par value; 300,000,000 shares authorized, 30,514,304 and 29,762,671 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. 
     -  
     - 
  
    Additional paid-in capital   
     38,327,799  
     31,239,895 
  
    Accumulated deficit 
     (37,846,576) 
     (30,596,858)
  
    Total stockholders’ equity 
     481,223  
     643,037 
  
    Total liabilities and stockholders’ equity  
    $829,611  
    $1,324,005 

See
notes to condensed unaudited financial statements

3

TELOMIR
PHARMACEUTICALS, INC.

CONDENSED
STATEMENTS OF OPERATIONS

FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Unaudited)

    2025  
    2024  
    2025